Acute intermittent porphyria is a neurologic disorder caused by a part
ial deficiency of porphobilinogen (PBG) deaminase, the third enzyme in
the synthetic pathway for heme. The isolation and characterization of
the gene for PBG deaminase has brought molecular techniques for diagn
osing the disease within reach. Over 60 mutations causing acute interm
ittent porphyria have been found, most of which are confined to one or
several families. Because no single mutation accounts for more than a
fraction of cases, screening techniques for locating and identifying
unknown mutations are very important. Once a mutation has been charact
erized, testing of family members is straightforward, and gene carrier
s can be identified or excluded with greater accuracy than is possible
with conventional biochemical tests.